Role of biomarkers in the diagnosis of bacterial infections in rheumatic diseases
https://doi.org/10.14412/1995-4484-2019-333-338
Abstract
In modern rheumatology, the problem of differential diagnosis of bacterial infection and active rheumatic process still retains its relevance. At the same time, it is very important to search for a biomarker - the gold standard for the diagnosis of an infection in patients with rheumatic diseases (RDs) in order to rapidly determine a treatment policy. This review analyzes the diagnostic significance and possibility of using some laboratory markers for bacterial infections in modern rheumatology. It emphasizes the importance of a multimarker approach that allows increasing the significance of individual parameters in the diagnosis of infections in RD.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
G. M. Tarasova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
N. V. Muravyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Белобородова НВ, Попов ДА. Тест на прокальцитонин: алгоритмы применения и новые возможности. Пособие для врачей. Москва; 2008. 74 с. [Beloborodova NV, Popov DA. Test na prokal'citonin: algoritmy primeneniya i novye vozmozhnosti. Posobie dlya vrachey [Procalcitonin test: application algorithms and new features. Manual for doctors]. Moscow; 2008.74 p. (In Russ.)].
2. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323(1-2):17-29. doi: 10.1016/S0009-8981(02)00101-8
3. Paosong S, Narongroeknawin P, Pakchotanon R, et al. Serum procalcitonin as a diagnostic aid in patients with acute bacterial septic arthritis. Int J Rheum Dis. 2015;18(3):352-9. doi: 10.1111/1756-185X.12496
4. Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and metaanalysis. Eur J Clin Microbiol Infect Dis. 2013;32(6):807-14. doi: 10.1007/s10096-012-1812-6
5. Choi ST, Song JS. Serum Procalcitonin as a Useful Serologic Marker for Differential Diagnosis between Acute Gouty Attack and Bacterial Infection. Yonsei Med J. 2016;57(5):1139-44. doi: 10.3349/ymj.2016.57.5.1139
6. Zhang J, Zhao C, Wu T, et al. Procalcitonin may not be a differential diagnostic marker for bacterial infection in febrile patients with chronic gouty arthritis. J Int Med Res. 2018;46(10):4197-206. doi: 10.1177/0300060518791093
7. Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and metaanalysis. Arthritis Rheum. 2012;64(9):3034-42. doi: 10.1002/art.34512
8. Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33 [Lapin SV, Maslyanskiy AL, Lazareva NM, et al. The value of quantitative analysis of procalcitonine in diagnostics of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya Laboratornaya Diagnostika. 2013;(1):28-33 (In Russ.)].
9. Тарасова ГМ, Белов Б.С, Дилбарян АГ, и др. Значение определения сывороточного прокальцитонина в дифференциальной диагностике инфекций и ревматических заболеваний. Медицинский совет. 2018;18:86-91 [Tarasova GM, Belov BS, Dilbaryan AG, et al. The value of determining serum procalcitonin in the differential diagnosis of infections and rheumatic diseases. Medicinskiy Sovet. 2018;18:86-91 (In Russ.)]. doi: 10.21518/2079-701X-2018-18-86-91
10. Ho W-L, Lan J-L, Chen D-Y, et al. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan J Rheumatol. 2009;23:52-8. doi: 10.1007/s10067-015-3020-0
11. Shin KC, Lee YJ, Kang SW, et al. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis. 2001;60(10):988-9. doi: 10.1136/ard.60.10.988
12. Liu LN, Wang P, Guan SY, et al. Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis. Rheumatol Int. 2017;37(12):1991-8. doi: 10.1007/s00296-017-3827-x
13. El-Serougy E, Zayed HS, Ibrahim NM, Maged LA. Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. Lupus. 2018 Jan 1:961203318777101. doi: 10.1177/096120331877710
14. Ospina FE, Echeverri A, Zambrano D, et al. Distinguishing infections vs flares in patients with systemic lupus erythematosus. Rheumatology. 2017;56(Suppl 1):i46-i54. doi: 10.1093/rheumatology/kew340
15. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250-6. doi: 10.1002/1529-0131(199707)40:7<1250::AIDART9>3.0.CO;2-A
16. Schwenger V, Sis J, Breitbart A, et al. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998;26(5):274-6. doi: 10.1007/BF02962246
17. Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123-8.
18. Chen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and noninfectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis. 2009;68(6):1074-5. doi: 10.1136/ard.2008.098335
19. Вельков ВВ. Пресепсин – эффективный биологический мар- кер для диагностики сепсиса и мониторинга системных ин- фекций. Здоровье. Медицинская экология. Наука. 2016;1(64):4-21 [Vel'kov VV. Presepsin is an effective biological marker for diagnosing sepsis and monitoring systemic infections. Zdorov'e. Medicinskaya ekologiya. Nauka. 2016;1(64):4-21 (In Russ.)].
20. Tsuji S, Kitatoube A, Kikuchi-Taura A, et al. Elevated soluble CD14-subtype (PRESEPSIN; P-SEP) levels in rheumatoid arthritis (RA) patients with bacterial infection. Mod Rheumatol. 2017;27(4):718-20. doi: 10.1080/14397595.2016.1246119
21. Oguro E, Tsuji S, Kuzuya K, et al. Serum presepsin as a novel biomarker for bacterial infection in rheumatoid arthritis patients treated with tocilizumab. Ann Rheum Dis. 2018;77(Suppl 2):296. doi: 10.1136/annrheumdis-2018-eular.3914
22. Tsujimoto K, Hata A, Fujita M, et al. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2018;21(7):1406-13. doi: 10.1111/1756-185X.12899
23. Tanimura S, Fujieda Y, Kono M, et al. Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. Modern Rheumatol. 2018;28(5):865-71. doi: 10.1080/14397595.2017
24. Yeh CF, Wu CC, Liu SH, Chen KF. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care. 2019 Jan 8;9(1):5. doi: 10.1186/s13613-018-0479-2
25. Echeverri A, Naranjo-Escobar J, Posso-Osorio I, et al. Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS. Lupus. 2018;27(7):1130-9. doi: 10.1177/0961203318763740
26. Feng M, Zhang SL, Liang ZJ, et al. Peripheral neutrophil CD64 index combined with complement, CRP, WBC count and B cells improves the ability of diagnosing bacterial infection in SLE. Lupus. 2019 Feb 2:961203319827646. doi: 10.1177/0961203319827646
27. Zhang J, She D, Feng D, et al. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis. 2011;11:53. doi: 10.1186/1471-2334-11-53
28. Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care. 2012;16(6):R229. doi: 10.1186/cc11884
29. Kim J, Koh JK, Lee EY, et al. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2009 Sep-Oct;27(5):773-8.
30. Molad Y, Pokroy-Shapira E, Kaptzan T, et al. Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection. Inflammation. 2013;36(6):1519-24. doi: 10.1007/s10753-013-9694-z
31. Ajmani S, Singh H, Chaturvedi S, et al. Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis. Clin Rheumatol. 2018 Nov 16. doi: 10.1007/s10067-018-4334-5
32. Lin CH, Hsieh SC, Keng LT, et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. PLoS One. 2016;11(4):e0153938. doi: 10.1371/journal.pone.0153938
33. Pliyev BK, Menshikov MY. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation. 2010;33(1):1-9. doi: 10.1007/s10753-009-9152-0
34. Zaitoon YA, Shehab AA, Mohamed NA. Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients. Egypt J Immunol. 2018 Jan;25(1):35-43.
35. Kurtipek GS, Kesli R, Tuncez Akyü rek F, et al. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity. Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(4):73-5. doi: 10.15570/actaapa.2015.19
36. Legany N, Toldi G, Distler JH, et al. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med. 2015 Oct;53(11):1799-805. doi: 10.1515/cclm-2015-0079
37. Xiao Y, Luo H, Zhou B, et al. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Rheumatol Int. 2017 Apr;37(4):585-92. doi: 10.1007/s00296-016-3609-x
38. Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные стандарты лабораторной диагностики ревматических заболеваний. Москва; 2012. 63 с. [Aleksandrova EN, Novikov AA, Nasonov EL. Sovremennye standarty laboratornoy diagnostiki revmaticheskih zabolevaniy [Modern standards for laboratory diagnosis of rheumatic diseases]. Moscow; 2012. 63 p. (In Russ.)].
39. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13(7):399-409. doi: 10.1038/nrrheum.2017.83
40. Holub M, Dzupova O, Ruzkova M, et al. Selected Biomarkers Correlate with the Origin and Severity of Sepsis. Mediators Inflamm. 2018 Mar 27;2018:7028267. doi: 10.1155/2018/7028267
41. Zhang Y, Khalid S, Jiang L. Diagnostic and predictive performance of biomarkers in patients with sepsis in an intensive care unit. J Int Med Res. 2019;47(1):44-58. doi: 10.1177/0300060518793791
42. Iwase S, Nakada TA, Hattori N, et al. Interleukin-6 as a diagnostic marker for infection in critically ill patients: A systematic review and meta-analysis. Am J Emerg Med. 2019;37(2):260-5. doi: 10.1016/j.ajem.2018.05.040
Review
For citations:
Belov B.S., Tarasova G.M., Muravyeva N.V. Role of biomarkers in the diagnosis of bacterial infections in rheumatic diseases. Rheumatology Science and Practice. 2019;57(3):333-338. (In Russ.) https://doi.org/10.14412/1995-4484-2019-333-338
Views:
694
Email this article 